Home » Stocks » ABUS

Arbutus Biopharma Corporation (ABUS)

Stock Price: $2.71 USD 0.06 (2.26%)
Updated May 11, 2021 10:07 AM EDT - Market open
Market Cap 258.51M
Revenue (ttm) 7.54M
Net Income (ttm) -78.62M
Shares Out 93.43M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $2.71
Previous Close $2.65
Change ($) 0.06
Change (%) 2.26%
Day's Open 2.53
Day's Range 2.45 - 2.78
Day's Volume 674,434
52-Week Range 1.45 - 9.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV...

6 days ago - GlobeNewsWire

WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chroni...

1 week ago - GlobeNewsWire

Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS...

1 month ago - Benzinga

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks

1 month ago - GlobeNewsWire

WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chroni...

1 month ago - GlobeNewsWire

Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 6.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 50.00% year over year to ($0.23), which missed ...

2 months ago - Benzinga

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favor...

2 months ago - GlobeNewsWire

Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-ca...

2 months ago - Benzinga

Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy

2 months ago - GlobeNewsWire

Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.

3 months ago - Seeking Alpha

2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs

3 months ago - GlobeNewsWire

WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p

5 months ago - GlobeNewsWire

Data released today expands on November 15, 2020 AASLD presentation

5 months ago - GlobeNewsWire

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted

5 months ago - GlobeNewsWire

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron...

6 months ago - GlobeNewsWire

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Arbutus (ABUS) delivered earnings and revenue surprises of -35.00% and -15.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chro...

7 months ago - GlobeNewsWire

Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety  and tolerability profile 

7 months ago - GlobeNewsWire

WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chro...

8 months ago - GlobeNewsWire

America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic.

Other stocks mentioned: AZN, JNJ, MRNA, NVAX, PFE
8 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the ...

8 months ago - GlobeNewsWire

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Is (ABUS) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

Short-term investors appear impatient.

9 months ago - The Motley Fool

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020

9 months ago - GlobeNewsWire

The biotech sector in the stock market has been on fire lately.

9 months ago - Seeking Alpha

WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron...

9 months ago - GlobeNewsWire

Here's what drove shares of these healthcare stocks through the roof last month.

Other stocks mentioned: ALT, OMI
9 months ago - The Motley Fool

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron...

9 months ago - GlobeNewsWire

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.

9 months ago - The Motley Fool

Arbutus Biopharma Corp. (NASDAQ: ABUS) stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moder...

9 months ago - 24/7 Wall Street

Arbutus Biopharma Corp. (NASDAQ: ABUS) shares jumped on Tuesday after the company reported positive data from its early stage clinical trial in patients with chronic hepatitis B virus (HBV) infection.

11 months ago - 24/7 Wall Street

 Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period

11 months ago - GlobeNewsWire

Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.

11 months ago - Zacks Investment Research

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

11 months ago - Zacks Investment Research

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-83... [Read more...]

Industry
Biotechnology
CEO
William Collier
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
ABUS
Full Company Profile

Financial Performance

In 2020, ABUS's revenue was $6.91 million, an increase of 15.02% compared to the previous year's $6.01 million. Losses were -$63.75 million, -58.53% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.07, which is an increase of 123.99% from the latest price.

Price Target
$6.07
(123.99% upside)
Analyst Consensus: Buy